NEW YORK – Illumina and Grail said on Monday morning that they have entered into a definitive acquisition agreement under which Illumina will purchase Grail for $8 billion in cash and stock. In addition, Grail shareholders will receive future payments tied to certain Grail-related revenues.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.